Economic Costs of Myasthenia Gravis: A Systematic Review

Table 3 Resources included in identified estimates of the direct medical cost of MG

Author (year)	Inpatient care	Outpatient care	Prescription drugs	OTC drugs	IVIG/PLEX	Co-payments
Ogino et al. (2017) [17]	×	×	×		NR
Sonkar et al. (2017) [20]	×	×	×	×	×	NA^a
Guptill et al. (2011) [11]	×	×	×	×	×^b
Guptill et al. (2012) [12]	×	×	×	×	×^b
Lai et al. and Tseng (2010) [14]	×	×			NR
Schepelmann et al. (2010) [19]	×	×	×	NR	NR	×

IVIG intravenous immunoglobulin, MG myasthenia gravis, NA not applicable, NR not reported (i.e. the information was not provided, but the specific resource category could have been included in the estimation, for example, as part of higher level cost categories), OTC over-the-counter, PLEX plasma exchange
^aThe direct medical cost was estimated based on patients’ out-of-pocket expenditure
^bExcluding inpatient IVIG costs